Recurrent Osteosarcoma Not Yet Recruiting Phase 2 Trials for Tipifarnib (DB04960)

Also known as: Osteosarcoma recurrent / Osteogenic sarcoma recurrent

IndicationStatusPhase
DBCOND0028757 (Recurrent Osteosarcoma)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04284774Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialTreatment